Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$17.99 USD
+0.34 (1.93%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $18.00 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.99 USD
+0.34 (1.93%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $18.00 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Zacks News
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Exact Sciences' (EXAS) revenues in the fourth quarter of 2023 are likely to have been driven by its flagship cancer screening tests, Cologuard and Oncotype DX.
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
by Kinjel Shah
Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR's (CRSP) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the launch activities of the newly approved gene therapy, Casgevy (exa-cel).
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Incyte's (INCY) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition recently.
Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2023 results.
Down -19.06% in 4 Weeks, Here's Why Intellia Therapeutics, Inc. (NTLA) Looks Ripe for a Turnaround
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Is it a Good Idea to Invest in Intellia (NTLA) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Intellia (NTLA) stock now may turn out to be a more prudent move than ever.
Is Intellia Therapeutics (NTLA) Stock a Solid Choice Right Now?
by Zacks Equity Research
Intellia Therapeutics (NTLA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
The Zacks Analyst Blog Highlights bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics
by Zacks Equity Research
bluebird, Editas Medicine, Beam Therapeutics and Intellia Therapeutics are part of the Zacks top Analyst Blog.
3 Biotechs With Promising Gene Therapies in the Spotlight
by Ekta Bagri
The recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline.
Intellia (NTLA) Rises on EC's Orphan Drug Tag for HAE Candidate
by Zacks Equity Research
The European Commission bestows orphan drug designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema. Stock rises.
Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update
by Zacks Equity Research
Intellia (NTLA) reports mixed third-quarter 2023 results. Management provides developmental and regulatory updates on its key pipeline candidates.
Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Beam Therapeutics Inc. (BEAM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia (NTLA) Focuses on Developing Gene-Editing Therapies
by Zacks Equity Research
Intellia's (NTLA) in-vivo CRISPR-based gene-edited therapy candidate NTLA-2001 holds potential. Other pipeline candidates are in early-stage development and progressing well.
Intellia's (NTLA) IND for Gene-Editing Therapy Gets FDA Clearance
by Zacks Equity Research
Intellia (NTLA) gets FDA nod to begin a phase III study on its gene editing candidate, NTLA-2001 to treat transthyretin amyloidosis with cardiomyopathy. The study is set to begin by 2023-end.
Intellia's (NTLA) HAE Candidate Gets EMA's PRIME Designation
by Zacks Equity Research
The European Medicines Agency bestows a Priority Medicines (PRIME) designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema.
The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna
by Zacks Equity Research
Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna are included in this Analyst Blog.
Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More
by Zacks Equity Research
Regulatory and pipeline updates from Novavax (NVAX) and ALX Oncology Holdings (ALXO) are in focus in the biotech sector.
Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies
by Zacks Equity Research
Intellia (NTLA) expands partnership with Regeneron, to develop potential treatments for neurological and muscular diseases.
Intellia (NTLA) Misses on Q2 Earnings, Gives Pipeline Update
by Zacks Equity Research
Intellia's (NTLA) second-quarter earnings miss estimates. The company provides an update on its gene-editing pipeline.
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -6.06% and 2.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Investors Increasingly Betting on Soft Landing As Inflation and Earnings Impress
by Mayur Thaker
Bets on a soft landing, with inflation cooling while jobs remain plentiful and earnings come in better than expected have fueled a speculative, multiple-expansion rally YTD. This is setting up an asymmetric risk-reward, in my opinion.
Intellia (NTLA) Up on Positive Data Updates From HAE Study
by Zacks Equity Research
Intellia's (NTLA) promising interim data on the early-stage study of NTLA-2002 shows potential as a single-dose treatment for hereditary angioedema.